GH Research, a clinical-stage biopharmaceutical company, reported a net loss of $48.3 million for the full year 2025. The company successfully completed its Phase 2b trial for GH001 in treatment-resistant depression, meeting its primary endpoint with significant MADRS reduction. The company maintains a strong cash position of $280.7 million to fund its upcoming Phase 3 pivotal program.

GH Research PLC reported a net loss of $10.8 million for Q1 2025, or $0.19 per share. The company met its primary endpoint in the Phase 2b trial for GH001 in TRD, showing a -15.5 point placebo-adjusted MADRS reduction. The company also reported a strong cash position of $315.3 million as of March 31, 2025, following a public offering that generated $150.0 million.